ARCHIVES

Somatuline Demonstrates 65.1 Percent Of Patients Progression-Free at 96 Weeks

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

September 27, 2013

ACS Honors Cady, Rimer For Work In Cancer Control.

December 8, 2000

Benefit Seen In Novel Drug That Treats Gleevec Resistance

April 29, 2005

NCI Cooperative Group, Cancer Center Trials Listed

October 26, 2007

Breast Cancer A Heterogeneous Disease, Concepts Changing: Fisher

June 13, 1980

New Tests Rule Out Theory On Polio Vaccine-AIDS Link.

October 6, 2000